SCOPUS 정보 검색 플랫폼

Volumn 55, Issue 6, 2013, Pages 508-510

Dipeptidyl peptidase-4 inhibitors: Their role in the management of type 2 diabetes

a NONE

Author keywords

Alogliptin; Dipeptidyl peptidase 4 (DPP 4) inhibitors; Glucagon like peptide 1 (GLP 1); Incretin hormones; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LINAGLIPTIN; LIRAGLUTIDE; NELFINAVIR; RITONAVIR; SAQUINAVIR; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ANGIONEUROTIC EDEMA; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMA; HEADACHE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 84892429663 PISSN: 20786190 EISSN: 20786204 Source Type: Journal
DOI: 10.1080/20786204.2013.10874407 Document Type: Article

Times cited : (7)

References (13)

1
- 84865722751
- The 2012 SEMDSA guideline for the management of type 2 diabetes (revised)
- Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes (revised). JEMDSA. 2012;17(2)(Supplement 1):S1-S95.
- (2012) JEMDSA. , vol.17 , Issue.2 SUPPL. 1
- Amod, A.¹ Ascott-Evans, B.H.² Berg, G.I.³

2
- 33749834648
- DPP-4 inhibitors and their potential role in the management of type 2 diabetes
- Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454-1470.
- (2006) Int J Clin Pract. , vol.60 , Issue.11 , pp. 1454-1470
- Barnett, A.¹

3
- 42449084168
- Dipeptidyl peptidase-IV inhibitors: Pharmacological profile and clinical use
- White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabet. 2008;26(2):53-57.
- (2008) Clin Diabet. , vol.26 , Issue.2 , pp. 53-57
- White, J.R.¹

4
- 79961222810
- Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences
- Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441-1467.
- (2011) Drugs. , vol.71 , Issue.11 , pp. 1441-1467
- Baetta, R.¹ Corsini, A.²

5
- 79959773411
- DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors
- Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34 Supplement 2:S276-S278.
- (2011) Diabetes Care. , vol.34 , Issue.SUPPL. 2
- Dicker, D.¹

6
- 70350475695
- Differential chemistry (structure), mechanism of action and pharmacology of GLP-receptor agonists and DPP-4 inhibitors
- Neumiller JJ. Differential chemistry (structure), mechanism of action and pharmacology of GLP-receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc. 2009;49 Suppl:S16-S29.
- (2009) J Am Pharm Assoc. , vol.49 , Issue.SUPPL.
- Neumiller, J.J.¹

7
- 84892427669
- MIMS, November
- MIMS, November 2012.
- (2012)

8
- 77955453343
- Dipeptidyl peptitase-4 inhibitors (gliptins). Focus on drug-drug interactions
- Scheen AJ. Dipeptidyl peptitase-4 inhibitors (gliptins). Focus on drug-drug interactions. Clin Pharmacokinetics. 2010;49(9):573-588.
- (2010) Clin Pharmacokinetics. , vol.49 , Issue.9 , pp. 573-588
- Scheen, A.J.¹

9
- 84892378747
- Onglyza® package insert
- Onglyza® package insert.

10
- 77957149259
- Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes
- Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. PT. 2010;35(9):509-513.
- (2010) PT. , vol.35 , Issue.9 , pp. 509-513
- Pathak, R.¹ Bridgeman, M.B.²

11
- 84892395243
- Galvus® package insert
- Galvus® package insert.

12
- 84892420622
- Galvus Met® package insert
- Galvus Met® package insert.

13
- 84892422273
- Januvia® package insert
- Januvia® package insert.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.